New obesity drug KAI-7535: when should you take it?

NCT ID NCT07294898

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study looked at how a low-fat meal and taking the drug in the evening affect levels of KAI-7535 in the blood. Eighteen healthy adults with overweight or obesity took the drug under different conditions. The goal was to understand the best way to take it, not to test weight loss itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

KAI-7535

What this could lead to

If successful, this could help determine the best way to take KAI-7535 for future weight-related treatments.

What could go wrong

This is a very early Phase 1 study with only 18 healthy participants, so results may not apply to patients or predict real-world effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anaheim Clinical Trials

    Anaheim, California, 92801, United States